Jeil Pharmaceutical Co.,Ltd (271980.KS)
KSE - KSE Delayed price. Currency in KRW
Add to watchlist
At close: 03:30PM KST
| Previous close | 15,550.00 |
| Open | 15,480.00 |
| Bid | 15,400.00 x 0 |
| Ask | 15,450.00 x 0 |
| Day's range | 15,400.00 - 15,800.00 |
| 52-week range | 14,540.00 - 19,870.00 |
| Volume | |
| Avg. volume | 81,474 |
| Market cap | 224.401B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 50.00 (0.32%) |
| Ex-dividend date | 27 Dec 2023 |
| 1y target est | N/A |
PR NewswireOnconic Therapeutics Announces Positive Phase 3 Results for JAQBO at Digestive Diseases Week 2024
Onconic Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for oncology and gastrointestinal disorders, announced today the results of its Phase 3 ZERO-1 study of JAQBO (zastaprazan citrate) at Digestive Disease Week (DDW) 2024, held in Washington D.C. from May 18-21, 2024.
- PR Newswire
Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)
Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in adults.
© 2024 Yahoo. All rights reserved.